| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Termination of a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities
As previously disclosed in its Current Report on Form 8-K filed on November 10, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement, dated November 10, 2023 (the “Loan Agreement”), with K2 Health... |
| 30 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint |
| 28 Oct 2026 | EFFECT |
| 26 Oct 2026 | S-3 |
| 26 Oct 2026 | 10-Q |
| 26 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Oct. 26, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ... |
| 16 Sep 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projec... |
| 12 Aug 2026 | DRS |
| 12 Aug 2026 | S-8 |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NEWTON, Mass., Aug. 12, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ... |
| 17 Jun 2026 |
Form 4: Porter Derrell, Director
Received 6,460 shares by exercise or conversion ($6.91K) · Sold 6,460 shares ($15.1K) · Sold 12,800 shares ($29.8K) · 2 more |
| 17 Jun 2026 | 144 |
| 16 Jun 2026 | 144 |
| 16 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease |
| 15 Jun 2026 | 144 |
| 10 Jun 2026 |
Form 4: Fountain Nathan B, Director
Sold 6,400 shares ($14.3K) |
| 09 Jun 2026 | 144 |
| 05 Jun 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Fountain Nathan B, Director
Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (right to buy) |
Loading...